Optimizing radioiodine for ablation of residual thyroid

The thyroid cancer (TC) has been studied in great detail in the form of the clinical experience during the past several decades. This has led to the retrospective analysis of various prognostic factors that have separated DTC into various risk groups. On one hand, the prognosis in the low-risk group is excellent with survival rate of 98 %, whereas the other end of the spectrum consists of high-risk group patients with poor survival, approximating only 50% at 10 years. Clearly, the understanding of the prognostic factors and risk groups is critically important in distinguishing a patient at low-risk from that at a high-risk which can make an impact in decision making regarding the extent of thyroidectomy and adjuvant treatment such as radioactive iodine (131I) therapy